Patients with chronic lymphocytic leukemia (CLL) have a suboptimal humoral response to
vaccination. Recently, BNT162b2, an mRNA COVID-19 vaccine with a high efficacy of 95 …

Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 …

Patients with chronic lymphocytic leukemia (CLL) have an impaired antibody response to
coronavirus disease 2019 (COVID-19) vaccination. Here, we evaluated the antibody …

Methods We examined 44 consecutive patients with CLL who received two doses of mRNA
vaccine (BNT162b2 or mRNA-1273) between 1/2/21 and 3/12/21 and were tested for anti …

Immunocompromised individuals such as patients with chronic lymphocytic leukemia (CLL)
are at risk of impaired immune responses to vaccination. The objective of our study was to …

B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and
patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines …

B cell chronic lymphocytic leukemia (CLL) is the most common subtype of adult leukemia
and is associated with profound secondary immunodeficiency. SARS-CoV-2 infection has …

Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently
treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies …

Chronic lymphocytic leukaemia (CLL) is associated with immunocompromise and high risk
of severe COVID‐19 disease and mortality. Monoclonal B‐cell lymphocytosis (MBL) patients …

Patients with chronic lymphocytic leukemia (CLL) or monoclonal B-lymphocytosis (MBL)
have impaired response to COVID-19 vaccination. A total of 258 patients (215 with CLL and …